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Objectives: Outcomes-based pricing and reimbursement arrangements (OPRAs), 
a type of performance-based risk-sharing (PBRS) arrangements, have emerged as a 
promising avenue for payers to share pharmaceutical risk and for manufacturers to 
improve access. The aim of this study was to explore the U.S. and EU-5 perspectives 
regarding historical and future activity for OPRAs as well as payers’ and manufactur-
ers’ perceptions of OPRAs. MethOds: Our study combined 2 approaches: targeted 
literature review and primary research with U.S. and EU-5 stakeholders. The targeted 
literature review included the following sources: University of Washington’s PBRS 
Database, payer and health technology assessment agencies’ websites, Factiva, 
PubMed, and congress abstracts. Only schemes relating to pharmaceuticals were 
included. Twenty-seven experts were interviewed using a structured questionnaire: 
14 US payers, 5 EU-5 national payers, 8 manufacturers’ pricing/market access execu-
tives (4 US, 4 EU-5). Results: A total of 117 arrangements were identified from 
1994 to 2014. This understates the level of OPRA activity as many schemes are 
confidential. U.S. and EU-5 interviewees expect that 2 to 10 times more OPRAs 
will be implemented in the next 5 years than in the previous 5 years. Historically, 
Italy has accounted for most OPRA activity; however, other nations are expected 
to increase OPRA activity. Key drivers include the introduction of a national OPRA 
framework in Spain, potentially a similar framework in the United Kingdom, a grow-
ing sick-fund activity in Germany, and a US movement towards accountable care. 
Motivation for OPRAs varies markedly across markets and stakeholders, with opera-
tional feasibility a significant hurdle in the U.S. and France. Cost and risk reduction 
were the primary focus for payers, while improving access was key for manufactur-
ers. cOnclusiOns: This research suggests high OPRA growth is expected in the 
EU-5 and, to a lesser extent in the U.S., particularly if clear, uncomplicated OPRA 
frameworks can be developed.
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Objectives: Pharmaceutical risk-sharing agreements are a type of contract 
between drug manufacturers and third party payers. These agreements are increas-
ingly being used as part of formulary listing decisions due to uncertainties about 
price and performance of new drugs at the time of launch. We develop a game 
theoretic model of a pay-for-performance agreement. MethOds: We model inter-
actions between the payer and manufacturer as a Stackelberg game. The pharma-
ceutical firm chooses the drug price and then the payer chooses which patients 
will be eligible for treatment. Following treatment the manufacturer pays a rebate 
to the payer for all patients who did not respond to the new drug. We solve for the 
optimal price and treatment decisions by both parties. We define the social welfare 
as the sum of the payer’s and manufacturer’s objective functions, and investigate 
whether a combination of taxes, subsidies and additional rebates can result in the 
optimal social welfare when the two parties act independently in a decentralized 
system. Results: We examine how the rebate rate determines the payer’s optimal 
treatment decisions. Specifically, we find a break-even threshold for the rebate rate 
for which the payer incurs neither a loss nor gain for patients not responding to the 
drug. We create several numerical examples to investigate how the distribution of 
the probability of success throughout the population influences the manufacturer’s 
profits and the net health benefits purchased by the payer. We find that a single 
rebate based on performance does not, in general, lead to a socially optimal out-
come, but that that socially optimal outcome can be achieved through additional 
rebates or by using appropriately designed taxes and subsidies. cOnclusiOns: A 
pay-for-performance risk-sharing agreement may be welfare-improving for certain 
ranges of rebate rate. Formulary managers should be aware of the incentives cre-
ated by different types of agreements when negotiating with drug manufacturers.
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Objectives: In August/2014 the Brazilian government opened for public consulta-
tion its bill on public-private partnerships (PDPs). The aim of this study is to under-
stand the current situation of the public-private partnership in Brazil. MethOds: 
We combined different database publicly available in the government website 
(www.saude.gov.br) encompassing: a) projects under analysis (submission period: 
March/2013-April/2014); b) products currently being purchased via PDPs; and c) 
projects rejected by the Ministry of Health. Results: There are 43 projects under 
analysis by the Ministry of Health, oncology representing over 50% of the submis-
sions. Government currently purchases 13 products from 7 official laboratories, vac-
cines being the main products. 151 projects were rejected by the Ministry of Health, 
participation of different therapeutic areas is fragmented. cOnclusiOns: To this 
point, data shows that vaccines are the key products in the PDP arena. However, 
according to recent submissions, oncology seems also to be a field of interest.
HEaltH carE usE & Policy studiEs – conceptual Papers
PHP178
tWo-Part Pricing for PatEnt ProtEctEd mEdicinEs â€ “an Economic 
analysis from a sWEdisH HEaltH carE PErsPEctivE
Hertzman P.G.1, Holm J.2
1Health Access Agency, Zurich, Switzerland, 2Lund University, Lund, Sweden
Two-Part Pricing for Patent Protected Medicines – An Economic Analysis from a 
Swedish Health Care Perspective Holm, H J and Hertzman, PObjectives: Many new 
medicines are targeting small patient populations. In order to recoup R&D costs the 
medicines are highly priced. A dilemma is that the price per patient (or pill or vial) can 
Objectives: To asses and obtain data on the proper use of drugs and present irrational 
drug use pattern by medical practitioners that weather the patients receive the medi-
cines, weather these are appropriate for their clinical needs, in proper doses, for appro-
priate periods of time, weather cost effective and were dispensed properly. MethOds: 
This study was designed to asses’ irrational drug use pattern which is a great concern of 
the entire world and WHO in general and in our country in particular. For this study we 
used the WHO indicators utilizing the services of trainee Pharmacists in two major city 
Hospitals. This study was conducted from April, 15th 2014 to May, 14th 2014. Data was 
collected using patient’s prescriptions and direct patient communication using a struc-
tured check list for the prescribing indicators including number of drugs per prescription, 
number of antibiotics, number of injections, number of steroids and number of food sup-
plements. The patient care data, including proper doses, proper timing, cost effectiveness 
and proper dispensing was directly interpreted and analyzed over the dispensing coun-
ters of Pharmacies by the trainee Pharmacists. Results: The results showed that in both 
hospitals (860 prescriptions), the average number of drugs per prescription were 5, the 
patients were prescribed antibiotics at least two antibiotics per prescription (40%).The 
percentage of injections, steroids and food supplements were 20% each. The percentage 
of proper doses, proper timing, cost effectiveness and proper dispensing was 70%, 60%, 
20% and 20% respectively. This irrational prescribing pattern/habit of the medical practi-
tioners was observed in both the hospitals. cOnclusiOns: This study indicates that this 
type of irrational practice is the reflection of state and regulatory affairs in the country 
and this is a warning for all developing countries which need strict regulations and strat-
egies for drug prescriptions and dispensing including the utilization of services of more 
Pharmacists.
HEaltH carE usE & Policy studiEs – risk sharing/Performance-based  
agreements
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Objectives: Step therapy is defined as the practice of beginning drug therapy 
for a medical condition with the safest and most cost-effective drug therapy and 
progressing to more risky or costly therapies. This analysis assessed the number 
of US health plans that require patients to step through a branded boxed warning 
product before initiating a branded non-boxed warning product. MethOds: This 
cross-sectional analysis was conducted using formulary data compiled by the MMIT 
Formulary Analytics Specialty Assessment database, which includes 2015 formulary 
status and policies for all US health plans. Of the 27 therapeutic classes that include 
products with a boxed warning, 9 therapeutic classes met all of the following criteria: 
(1) include currently marketed branded products, (2) include branded boxed warning 
products, (3) include branded non-boxed warning products, (4) include specialty or 
small-molecule products. Formulary requirements and restrictions for the 30 largest 
commercial US health plans were examined for cases in which patients are required 
by formulary design to step through a branded drug with a boxed warning before 
initiating a product without a boxed warning. Results: The 30 commercial plans 
represented 121 million lives, or 56% of the 217 million commercial lives in the United 
States. The number of health plans requiring patients to step through a branded 
boxed warning drug before initiating a non-boxed warning product in the 9 thera-
peutic classes included were: anti-infectives (miscellaneous), 0; anticonvulsants, 0; 
antidiabetics, 0; gastrointestinal agents, 0; immunological agents and biologics, 18 
(45% of covered lives); respiratory agents, 0; dermatologic agents, 0; central nervous 
system drugs (anti-Parkinson), 0; and renal agents, 0. cOnclusiOns: The designs of 
US formularies generally do not require a step through products with a box warning 
prior to initiating a product without a boxed warning. The one notable exception is 
the class of immunological agents and biologics.
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Objectives: To identify the key milestones for the public-private partner-
ships in Brazil. MethOds: We conducted a literature review (2004-2014) on the 
legislation and local articles about public-private partnership (PPP) for drugs in 
Brazil. Results: In 2004 the government issued law #11079 establishing general 
rules for PPPs in all sectors. The first specific mention to healthcare was done in 
the article ‘Development, health-industrial complex and industrial policy’ (Gadelha, 
2006). In 2010 via the decree #1284 the government sets its list with the strategic 
products for the healthcare public system. Still in 2010 law #12349 creates the prefer-
ence margin benefiting in bids/tenders products locally produced. In 2013 in “Brasil 
Maior” plan the government formalizes its aim to achieving autonomy in producing 
strategic drugs via partnerships for productive development (PDP). More recently, 
public consultation #8 was opened in August/2014 with the content of the bill which 
aims to set criteria and guidelines for the PDPs. cOnclusiOns: For the last 10 years 
the Brazilian government has consistently put in place either legislation or initiates 
to achieve autonomy in producing key products for the public healthcare system.
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